Skip to main content
SpringerLink
Log in

Prognostic Factors

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

The concept that Hodgkin lymphoma (then called Hodgkin’s disease) passes through successive clinical stages with increasing spread of the disease and progressive worsening of prognosis was developed early on. Different staging classifications were proposed based on the anatomic extent of disease. A consensus was reached at the Workshop on the Staging of Hodgkin’s Disease at Ann Arbor in 1971, and the Ann Arbor staging classification was universally adopted. It remains the basis for the evaluation of patients with Hodgkin lymphoma, and its prognostic significance has been documented in numerous studies of patients treated with different treatment modalities. Survival curves according to Ann Arbor stage for more than 8,000 patients from the United States National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) programme are shown in Fig. 8.1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ABVD:

Adriamycin, bleomycin, vinblastine, dacarbazine

BEACOPPesc:

Bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, prednisolone, escalated

BNLI:

British National Lymphoma Investigation

CALGB:

Cancer and Leukemia Group B

ECOG:

Eastern Cooperative Oncology Group

ESR:

Erythrocyte sedimentation rate

EORTC:

European Organization for Research and Treatment of Cancer

FDG:

2-[18F]fluoro-2-deoxy-D-glucose

GELA:

Groupe d’Etudes des Lymphomes de l’Adulte

GHSG:

German Hodgkin Lymphoma Study Group

IPS:

International Prognostic Score

LDH:

Lactic dehydrogenase

MOPP:

Mechlorethamine, vincristine, procarbazine, prednisolone

NCI-C:

National Cancer Institute of Canada

NCI-US:

National Cancer Institute of the United States

PET:

Positron emission tomography

SWOG:

Southwest Oncology Group

References

  1. Reed DM (1902) On the pathological changes in Hodgkin’s disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 10:133–196

    Google Scholar 

  2. Banfi A, Bonadonna G, Buraggi G et al (1965) Proposta di classificazione e terapia della malattia di Hodgkin. Tumori 51:97–112

    CAS  PubMed  Google Scholar 

  3. Easson EC, Russell MH The cure of Hodgkin’s disease. BMJ 1963;1:1704–1707

    Google Scholar 

  4. Jelliffe AM, Thomson AD (1955) The prognosis in Hodgkin’s disease. Br J Cancer 9:21–36

    CAS  PubMed Central  PubMed  Google Scholar 

  5. Kaplan HS (1970) On the natural history, treatment and prognosis of Hodgkin’s disease. I: Harvey Lectures 1968–1969. Academic, New York, pp 215–259

    Google Scholar 

  6. Musshoff K, Stamm H, Lummel G, Gössel K (1964) Zur prognose der lymphogranulomatose. Klinisches bild und strahlentherapie. Freiburger Krankengut 1938–1958. I. In: Keiderling W (ed) Beiträge zur Inneren Medizin. FK Schattauer-Verlag, Stuttgart, pp 549–561

    Google Scholar 

  7. Peters MV (1950) A study of survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol 63:299–311

    Google Scholar 

  8. Rosenberg SA (1966) Report of the committee on the staging of Hodgkin’s disease. Cancer Res 26:1310–1310

    Google Scholar 

  9. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  10. Aisenberg AC, Qazi R (1976) Improved survival in Hodgkin’s disease. Cancer 37:2423–2429

    CAS  PubMed  Google Scholar 

  11. Davis S, Dahlberg S, Myers MH, Chen A, Steinhorn SC (1987) Hodgkin’s disease in the United States: a comparison of patient characteristics and survival in the centralized cancer patient data system and the surveillance, epidemiology, and end results program. J Natl Cancer Inst 78:471–478

    CAS  PubMed  Google Scholar 

  12. Gobbi PG, Cavalli C, Federico M, Bertoloni D, Di Prisco UA, Rossi A, Silingardi V, Mauri C, Ascari E (1988) Hodgkin’s disease prognosis: a directly predictive equation. Lancet 1:675–679

    CAS  PubMed  Google Scholar 

  13. Hancock BW, Aitken M, Martin JF, Dunsmore IR, Ross CM, Carr I, Emmanuel IG (1979) Hodgkin’s disease in Sheffield (1971–76) (with computer analysis of variables). Clin Oncol 5:283–297

    CAS  PubMed  Google Scholar 

  14. Henry-Amar M, Aeppli DM, Anderson J, Ashley S, Bonichon F, Cox RS, Dahlberg SJ, DeBoer G, Dixon DO, Gobbi PG, Gregory W, Hasenclever D, Löffler M, Pompe Kirn V, Santarelli MT, Specht L, Swindell R, Vaughan Hudson B (1990) Workshop statistical report. I. In: Somers R, Henry-Amar M, Meerwaldt JH, Carde P (eds) Treatment strategy in Hodgkin’s disease. INSERM/John Libbey Eurotext, London, pp 169–425

    Google Scholar 

  15. Kaplan HS (1973) Survival and relapse rates in Hodgkin’s disease: Stanford experience, 1961–71. Monogr Natl Cancer Inst 36:487–496

    CAS  Google Scholar 

  16. Musshoff K, Hartmann C, Niklaus B, Rössnere R (1974) Results of therapy in Hodgkin’s disease: Freiburg i. Br. 1964–1971. I. In: Musshoff K (ed) Diagnosis and therapy of malignant lymphoma. Springer, Berlin, pp 206–220

    Google Scholar 

  17. Sutcliffe SB, Gospodarowicz MK, Bergsagel DE, Bush RS, Alison RE, Bean HA, Brown TC, Chua T, Clark RM, Curtis JE (1985) Prognostic groups for management of localized Hodgkin’s disease. J Clin Oncol 3:393–401

    CAS  PubMed  Google Scholar 

  18. Clarke CA, Glaser SL, Prehn AW (2001) Age-specific survival after Hodgkin’s disease in a population-based cohort (United States). Cancer Causes Control 12:803–812

    CAS  PubMed  Google Scholar 

  19. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630–1636

    CAS  PubMed  Google Scholar 

  20. George SL (1988) Identification and assessment of prognostic factors. Semin Oncol 15:462–471

    CAS  PubMed  Google Scholar 

  21. Gospodarowicz MK, O’Sullivan B, Koh ES (2006) Prognostic factors: principles and applications. I. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds) Prognostic factors in cancer, 3rd edn. Wiley-Liss, Hoboken, pp 23–38

    Google Scholar 

  22. Byar DP (1988) Identification of prognostic factors. I. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials. Methods and practice. Oxford University Press, Oxford, pp 423–443

    Google Scholar 

  23. Riley RD, Sauerbrei W, Altman DG (2009) Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100:219–1229

    Google Scholar 

  24. Byar DP (1991) Problems with using observational databases to compare treatments. Stat Med 10:663–666

    CAS  PubMed  Google Scholar 

  25. Simon R (1984) Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 68:185–192

    CAS  PubMed  Google Scholar 

  26. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    PubMed  Google Scholar 

  27. Altman DG (2006) Studies investigating prognostic factors: conduct and evaluation. I. In: Gospodarowicz MK, O’Sullivan B, Sobin LH (eds) Prognostic factors in cancer, 3rd edn. Wiley-Liss, Hoboken, pp 39–54

    Google Scholar 

  28. Burke HB, Henson DE (1993) The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72:3131–3135

    CAS  PubMed  Google Scholar 

  29. Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34:187–220

    Google Scholar 

  30. Simon R (2001) Evaluating prognostic factor studies. I. In: Gospodarowicz MK, Henson DE, Hutter RVP, O’Sullivan B, Sobin LH, Wittekind C (eds) Prognostic factors in cancer, 2nd edn. Wiley-Liss, New York, pp 49–56

    Google Scholar 

  31. Kaplan HS, Dorfman RF, Nelsen TS, Rosenberg SA (1973) Staging laparotomy and splenectomy in Hodgkin’s disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients. Natl Cancer Inst Monogr 36:291–301

    CAS  PubMed  Google Scholar 

  32. Piro AJ, Hellman S, Moloney WC (1972) The influence of laparotomy on management decisions in Hodgkin’s disease. Arch Intern Med 130:844–848

    CAS  PubMed  Google Scholar 

  33. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59:455–465

    CAS  PubMed  Google Scholar 

  34. Horwich A, Easton D, Nogueira-Costa R, Liew KH, Colman M, Peckham MJ (1986) An analysis of prognostic factors in early stage Hodgkin’s disease. Radiother Oncol 7:95–106

    CAS  PubMed  Google Scholar 

  35. Mauch P, Tarbell N, Weinstein H, Silver B, Goffman T, Osteen R, Zajac A, Coleman CN, Canellos G, Rosenthal D (1988) Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576–1583

    CAS  PubMed  Google Scholar 

  36. Tubiana M, Henry-Amar M, Hayat M, Burgers M, Qasim M, Somers R, Sizoo W, Van der Schueren E (1984) Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 54:885–894

    CAS  PubMed  Google Scholar 

  37. Willett CG, Linggood RM, Leong JC, Miketic LM, Stracher MA, Skates SJ, Kushner DC (1988) Stage IA to IIB mediastinal Hodgkin’s disease: three-dimensional volumetric assessment of response to treatment. J Clin Oncol 6:819–824

    CAS  PubMed  Google Scholar 

  38. Enblad G (1994) Hodgkin’s disease in young and elderly patients. Clinical and pathological studies. Minireview based on a doctoral thesis. Ups J Med Sci 99:1–38

    CAS  PubMed  Google Scholar 

  39. Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI (1988) Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 61:1719–1727

    CAS  PubMed  Google Scholar 

  40. Specht L (1992) Tumour burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer 28A:1982–1985

    CAS  PubMed  Google Scholar 

  41. Hoppe RT, Horning SJ, Rosenberg SA (1985) The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin’s disease. Cancer Surv 4:459–475

    CAS  PubMed  Google Scholar 

  42. Mauch P, Gorshein D, Cunningham J, Hellman S (1982) Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin’s disease. Cancer Treat Rep 66:809–817

    CAS  PubMed  Google Scholar 

  43. Specht L (1991) Prognostic factors in Hodgkin’s disease. Cancer Treat Rev 18:21–53

    CAS  PubMed  Google Scholar 

  44. Tarbell NJ, Thompson L, Mauch P (1990) Thoracic irradiation in Hodgkin’s disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 18:275–281

    CAS  PubMed  Google Scholar 

  45. Connors JM, Klimo P (1984) Is it an E lesion or stage IV? An unsettled issue in Hodgkin’s disease staging. J Clin Oncol 2:1421–1423

    CAS  PubMed  Google Scholar 

  46. Franklin J, Paulus U, Lieberz D, Breuer K, Tesch H, Diehl V (2000) Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Ann Oncol 11:617–623

    CAS  PubMed  Google Scholar 

  47. Gobbi PG, Gendarini A, Crema A, Cavalli C, Attardo-Parrinello G, Federico M, Di Prisco U, Ascari E (1985) Serum albumin in Hodgkin’s disease. Cancer 55:389–393

    CAS  PubMed  Google Scholar 

  48. Gospodarowicz MK, Sutcliffe SB, Clark RM, Dembo AJ, Fitzpatrick PJ, Munro AJ, Bergsagel DE, Patterson BJ, Tsang R, Chua T (1992) Analysis of supradiaphragmatic clinical stage I and II Hodgkin’s disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22:859–865

    CAS  PubMed  Google Scholar 

  49. Tubiana M, Henry-Amar M, Werf-Messing B, Henry J, Abbatucci J, Burgers M, Hayat M, Somers R, Laugier A, Carde P (1985) A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11:23–30

    CAS  PubMed  Google Scholar 

  50. Vaughan Hudson B, MacLennan KA, Bennett MH, Easterling MJ, Vaughan Hudson G, Jelliffe AM (1987) Systemic disturbance in Hodgkin’s disease and its relation to histopathology and prognosis (BNLI report No. 30). Clin Radiol 38:257–261

    CAS  PubMed  Google Scholar 

  51. Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Ferme C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J (2006) Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 17:1749–1760

    CAS  PubMed  Google Scholar 

  52. Specht L, Gray RG, Clarke MJ, Peto R (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 16:830–843

    CAS  PubMed  Google Scholar 

  53. Specht L (2003) Very long-term follow-up of the Danish National Hodgkin Study Group’s randomized trial of radiotherapy (RT) alone vs. combined modality treatment (CMT) for early stage Hodgkin lymphoma, with special reference to second tumours and overall survival. Blood 102:637A

    Google Scholar 

  54. Bonfante V, Santoro A, Viviani S, Zucali R, Devizzi L, Zanini M, Tess JDT, Valagussa P, Banfi A, Bonadonna G (1993) Early stage Hodgkin’s disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer 29A:24–29

    Google Scholar 

  55. Glimelius I, Molin D, Amini RM, Gustavsson A, Glimelius B, Enblad G (2003) Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haematol 71:327–333

    PubMed  Google Scholar 

  56. Pavlovsky S, Maschio M, Santarelli MT, Muriel FS, Corrado C, Garcia I, Schwartz L, Montero C, Sanahuja FL, Magnasco O (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 80:1466–1473

    CAS  PubMed  Google Scholar 

  57. Tubiana M, Henry-Amar M, Carde P, Burgers JM, Hayat M, van der Schueren E, Noordijk EM, Tanguy A, Meerwaldt JH, Thomas J (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73:47–56

    CAS  PubMed  Google Scholar 

  58. Gobbi PG, Ghirardelli ML, Solcia M, Di Giulio G, Merli F, Tavecchia L, Berte R, Davini O, Levis A, Broglia C, Maffe GC, Ilariucci F, Dore R, Ascari E (2001) Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance. J Clin Oncol 19:1388–1394

    CAS  PubMed  Google Scholar 

  59. Gobbi PG, Broglia C, Di Giulio G, Mantelli M, Anselmo P, Merli F, Zinzani PL, Rossi G, Callea V, Iannitto E, Paulli M, Garioni L, Ascari E (2004) The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 101:1824–1834

    PubMed  Google Scholar 

  60. Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, Luminari S, Polimeno G, Federico M (2012) Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol 30:194–199

    PubMed  Google Scholar 

  61. Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Federico M (2013) Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. Hematol Oncol 31:151–155

    CAS  PubMed  Google Scholar 

  62. Gobbi PG (2014) Tumor burden in Hodgkin’s lymphoma: much more than the best prognostic factor. Crit Rev Oncol Hematol 90:17–23

    PubMed  Google Scholar 

  63. Grow A, Quon A, Graves EE, Loo BW (2005) Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol 23(Suppl):583S

    Google Scholar 

  64. Hutchings M, Berthelsen AK, Jakobsen AL, Specht L (2005) Volume of abnormal tumour tissue on FDG-PET–a predictor of progression-free survival in Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 63:S45

    Google Scholar 

  65. Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, Chong A, Moon JH, Kim JH, Lee SM, Kim SJ, Shin HJ (2013) Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci 104:1656–1661

    CAS  PubMed  Google Scholar 

  66. Filippi AR, Botticella A, Bello M, Botto B, Castiglione A, Gavarotti P, Gottardi D, Parvis G, Bisi G, Levis A, Vitolo U, Ricardi U (2013) Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk Lymphoma 54:1183–1187

    CAS  PubMed  Google Scholar 

  67. Gallamini A, Kostakoglu L (2012) Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 120:4913–4920

    CAS  PubMed  Google Scholar 

  68. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59

    CAS  PubMed  Google Scholar 

  69. Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M (2014) In-vivo treatment sensitivity testing with PET/CT after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol 32:2705–2711

    Google Scholar 

  70. Kostakoglu L, Schoder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD (2012) Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 53:2143–2150

    CAS  PubMed  Google Scholar 

  71. Sher DJ, Mauch PM, van den Abbeele A, LaCasce AS, Czerminski J, Ng AK (2009) Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol 20:1848–1853

    CAS  PubMed  Google Scholar 

  72. Diefenbach C, Steidl C (2013) New strategies in Hodgkin lymphoma: better risk profiling and novel treatments. Clin Cancer Res 19:2797–2803

    CAS  PubMed Central  PubMed  Google Scholar 

  73. Hagenbeek A, Gascoyne RD, Dreyling M, Kluin P, Engert A, Salles G (2009) Biomarkers and prognosis in malignant lymphomas. Clin Lymphoma Myeloma 9:160–166

    CAS  PubMed  Google Scholar 

  74. Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F, Tan KL, Gascoyne RD, Gordon LI, Fisher RI, Bartlett NL, Stiff P, Cheson BD, Advani R, Miller TP, Kahl BS, Horning SJ, Ambinder RF (2013) Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121:3547–3553

    CAS  PubMed Central  PubMed  Google Scholar 

  75. Mestre F, Gutierrez A, Ramos R, Martinez-Serra J, Sanchez L, Matheu G, Ros T, Garcia JF, Rodriguez J (2012) Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood 119:6072–6079

    CAS  PubMed  Google Scholar 

  76. Navarro A, Munoz C, Gaya A, Diaz-Beya M, Gel B, Tejero R, Diaz T, Martinez A, Monzo M (2013) MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients. PLoS One 8:e64716

    PubMed Central  PubMed  Google Scholar 

  77. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD (2013) Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 31:692–700

    PubMed Central  PubMed  Google Scholar 

  78. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362:875–885

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A (2010) Combined modality treatment improves tumour control and overall survival in patients with early stage Hodgkin lymphoma: a systematic review. Haematologica 95:494–500

    CAS  PubMed Central  PubMed  Google Scholar 

  80. Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 16:818–829

    CAS  PubMed  Google Scholar 

  81. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514

    CAS  PubMed  Google Scholar 

  82. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484

    CAS  PubMed  Google Scholar 

  83. Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E (1997) Prognosis of patients with advanced Hodgkin’s disease: evaluation of four prognostic models using 344 patients included in the Group d’Etudes des Lymphomes de l’Adulte Study. Cancer 80:1124–1133

    CAS  PubMed  Google Scholar 

  84. Low SE, Horsman JM, Walters SJ, Hancock H, Smith P, Linch D, Hancock BW (2003) Risk-adjusted prognostic models for Hodgkin’s disease (HD) and grade II non-Hodgkin’s lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients. Br J Haematol 120:277–280

    PubMed  Google Scholar 

  85. Peterson BA, Pajak TF, Cooper MR, Nissen NI, Glidewell OJ, Holland JF, Bloomfield CD, Gottlieb AJ (1982) Effect of age on therapeutic response and survival in advanced Hodgkin’s disease. Cancer Treat Rep 66:889–898

    CAS  PubMed  Google Scholar 

  86. Proctor SJ, Taylor P, Donnan P, Boys R, Lennard A, Prescott RJ (1991) A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 27:624–629

    CAS  PubMed  Google Scholar 

  87. Sjoberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, Bjorkholm M (2012) Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood 119:990–996

    PubMed  Google Scholar 

  88. Specht L, Nissen NI (1988) Prognostic factors in Hodgkin’s disease stage IV. Eur J Haematol 41:359–367

    CAS  PubMed  Google Scholar 

  89. Specht L, Nissen NI (1988) Prognostic factors in Hodgkin’s disease stage III with special reference to tumour burden. Eur J Haematol 41:80–87

    CAS  PubMed  Google Scholar 

  90. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD (1990) Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross- resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8:1173–1186

    CAS  PubMed  Google Scholar 

  91. Proctor SJ, Rueffer JU, Angus B, Breuer K, Flechtner H, Jarrett R, Levis A, Taylor P, Tirelli U (2002) Hodgkin’s disease in the elderly: current status and future directions. Ann Oncol 13(Suppl 1):133–137

    PubMed  Google Scholar 

  92. Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Duhmke E, Muller-Hermelink K, Diehl V (2005) Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol 23:5052–5060

    PubMed  Google Scholar 

  93. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW (2005) Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41:1051–1057

    PubMed  Google Scholar 

  94. Boll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, von Tresckow B, Eichenauer DA, Sasse S, Fuchs M, Behringer K, Klimm BC, Naumann R, Diehl V, Engert A, Borchmann P (2013) Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 31:4431–4437

    PubMed  Google Scholar 

  95. Gobbi PG, Comelli M, Grignani GE, Pieresca C, Bertoloni D, Ascari E (1994) Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD). Haematologica 79:241–255

    CAS  PubMed  Google Scholar 

  96. Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A (2005) Role of hematotoxicity and sex in patients with Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 23:8003–8011

    CAS  PubMed  Google Scholar 

  97. Allemani C, Sant M, De AR, Marcos-Gragera R, Coebergh JW (2006) Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 107:352–360

    PubMed  Google Scholar 

  98. Henry-Amar M, Hayat M, Meerwaldt JH, Burgers M, Carde P, Somers R, Noordijk EM, Monconduit M, Thomas J, Cosset JM (1990) Causes of death after therapy for early stage Hodgkin’s disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys 19:1155–1157

    CAS  PubMed  Google Scholar 

  99. Ranson MR, Radford JA, Swindell R, Deakin DP, Wilkinson PM, Harris M, Johnson RJ, Crowther D (1991) An analysis of prognostic factors in stage III and IV Hodgkin’s disease treated at a single centre with MVPP. Ann Oncol 2:423–429

    CAS  PubMed  Google Scholar 

  100. Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L (1994) A randomized study in stage IIIB and IV Hodgkin’s disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12:279–287

    CAS  PubMed  Google Scholar 

  101. Georgii A, Fischer R, Hubner K, Schwarze EW, Bernhards J (1993) Classification of Hodgkin’s disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial. Leuk Lymphoma 9:365–370

    CAS  PubMed  Google Scholar 

  102. Glaser SL, Dorfman RF, Clarke CA (2001) Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates. Cancer 92:218–224

    CAS  PubMed  Google Scholar 

  103. Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Stelitano C, Iannitto E, Federico M (2012) Tumor burden in Hodgkin’s lymphoma can be reliably estimated from a few staging parameters. Oncol Rep 28:815–820

    CAS  PubMed  Google Scholar 

  104. Torricelli P, Grimaldi PL, Fiocchi F, Federico M, Romagnoli R (2004) Hodgkin’s disease: a quantitative evaluation by computed tomography of tumor burden. Clin Imaging 28:239–244

    PubMed  Google Scholar 

  105. Hoppe RT, Cox RS, Rosenberg SA, Kaplan HS (1982) Prognostic factors in pathologic stage III Hodgkin’s disease. Cancer Treat Rep 66:743–749

    CAS  PubMed  Google Scholar 

  106. Mauch P, Goffman T, Rosenthal DS, Canellos GP, Come SE, Stage HS, III (1985) Hodgkin’s disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol 3:1166–1173

    CAS  PubMed  Google Scholar 

  107. Powlis WD, Mauch P, Goffman T, Goodman RL (1987) Treatment of patients with “minimal” stage IIIA Hodgkin’s disease. Int J Radiat Oncol Biol Phys 13:1437–1442

    CAS  PubMed  Google Scholar 

  108. Stein RS, Golomb HM, Wiernik PH, Mauch P, Hellman S, Ultmann JE, Rosenthal DS, Flexner JM (1982) Anatomic substages of stage IIIA Hodgkin’s disease: followup of a collaborative study. Cancer Treat Rep 66:733–741

    CAS  PubMed  Google Scholar 

  109. Brada M, Ashley S, Nicholls J, Wist E, Colman M, McElwain TJ, Selby P, Peckham MJ, Stage HA, III (1989) Hodgkin’s disease–long-term results following chemotherapy, radiotherapy and combined modality therapy. Radiother Oncol 14:185–198

    CAS  PubMed  Google Scholar 

  110. Desser RK, Golomb HM, Ultmann JE, Ferguson DJ, Moran EM, Griem ML, Vardiman J, Miller B, Oetzel N, Sweet D, Lester EP, Kinzie JJ, Blough R (1977) Prognostic classification of Hodgkin disease in pathologic stage III, based on anatomic considerations. Blood 49:883–893

    CAS  PubMed  Google Scholar 

  111. Golomb HM, Sweet DL, Ultmann JE, Miller JB, Kinzie JJ, Gordon LI (1980) Importance of substaging of stage III Hodgkin’s disease. Semin Oncol 7:136–143

    CAS  PubMed  Google Scholar 

  112. Proctor SJ, Taylor P, Mackie MJ, Donnan P, Boys R, Lennard A, Prescott RJ (1992) A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma 7(Suppl):17–20

    PubMed  Google Scholar 

  113. Hasenclever D, Schmitz N, Diehl V (1995) Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin’s disease? German Hodgkin’s Lymphoma Study Group (GHSG). Leuk Lymphoma 15(Suppl 1):47–49

    PubMed  Google Scholar 

  114. Gobbi PG, Cavalli C, Gendarini A, Bonfichi M, Galeone F, Inzoli A, Ascari E (1986) Prognostic significance of serum albumin in Hodgkin’s disease. Haematologica 71:95–102

    CAS  PubMed  Google Scholar 

  115. Straus DJ (1995) High-risk Hodgkin’s disease prognostic factors. Leuk Lymphoma 15(Suppl 1):41–42

    PubMed  Google Scholar 

  116. Loeffler M, Pfreundschuh M, Hasenclever D, Hiller E, Gerhartz H, Wilmanns W, Rohloff R, Ruhl U, Kuhn G, Fuchs R (1988) Prognostic risk factors in advanced Hodgkin’s lymphoma. Report of the German Hodgkin Study Group. Blut 56:273–281

    CAS  PubMed  Google Scholar 

  117. Wagstaff J, Gregory WM, Swindell R, Crowther D, Lister TA (1988) Prognostic factors for survival in stage IIIB and IV Hodgkin’s disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer 58:487–492

    CAS  PubMed Central  PubMed  Google Scholar 

  118. MacLennan KA, Vaughan Hudson B, Easterling MJ, Jelliffe AM, Vaughan Hudson G, Haybittle JL (1983) The presentation haemoglobin level in 1103 patients with Hodgkin’s disease (BNLI report no. 21). Clin Radiol 34:491–495

    CAS  PubMed  Google Scholar 

  119. Brusamolino E, Orlandi E, Morra E, Castelli G, Pagnucco G, Livraghi A, Astori C, Santagostino A, Lazzarino M, Bernasconi C (1994) Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin’s disease treated with the alternating MOPP/ABVD chemotherapy. Ann Oncol 5(Suppl 2):53–57

    PubMed  Google Scholar 

  120. Carde P, MacKintosh FR, Rosenberg SA (1983) A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1:146–153

    CAS  PubMed  Google Scholar 

  121. DeVita VT Jr, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH III, Frei E III, Carbone PP, Canellos GP (1980) Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587–595

    PubMed  Google Scholar 

  122. Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V (1995) Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s lymphoma study group. J Clin Oncol 13:403–409

    CAS  PubMed  Google Scholar 

  123. Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. A report of 8-year results. Ann Intern Med 104:739–746

    CAS  PubMed  Google Scholar 

  124. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4:1295–1306

    CAS  PubMed  Google Scholar 

  125. Selby P, Patel P, Milan S, Meldrum M, Mansi J, Mbidde E, Brada M, Perren T, Forgeson G, Gore M (1990) ChlVPP combination chemotherapy for Hodgkin’s disease: long-term results. Br J Cancer 62:279–285

    CAS  PubMed Central  PubMed  Google Scholar 

  126. Jaffe HS, Cadman EC, Farber LR, Bertino JR (1986) Pretreatment hematocrit as an independent prognostic variable in Hodgkin’s disease. Blood 68:562–564

    CAS  PubMed  Google Scholar 

  127. Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, Butler JJ, Shullenberger CC (1985) Prognostic factors for Stage IV Hodgkin’s disease treated with MOPP, with or without bleomycin. Cancer 55:691–697

    CAS  PubMed  Google Scholar 

  128. Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB (1993) Prognostic role of serum beta 2-microglobulin in Hodgkin’s disease. J Clin Oncol 11:1108–1111

    CAS  PubMed  Google Scholar 

  129. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Karkantaris C, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Pizzolo G, Pangalis GA (2002) The prognostic significance of beta(2)-microglobulin in patients with Hodgkin’s lymphoma. Haematologica 87:701–708

    CAS  PubMed  Google Scholar 

  130. Gause A, Jung W, Keymis S, Schobert I, Scholz R, Schmits R, Diehl V, Pohl C, Hasenclever D, Pfreundschuh M (1992) The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin’s disease. Leuk Lymphoma 7:439–447

    CAS  PubMed  Google Scholar 

  131. Gause A, Jung W, Schmits R, Tschiersch A, Scholz R, Pohl C, Hasenclever D, Diehl V, Pfreundschuh M (1992) Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin’s lymphoma. Ann Oncol 3(Suppl 4):49–52

    PubMed  Google Scholar 

  132. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 12:793–797

    CAS  PubMed  Google Scholar 

  133. Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H (1990) Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin’s disease: relationship with disease activity and clinical stage. Br J Haematol 75:282–284

    CAS  PubMed  Google Scholar 

  134. Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M (2000) Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin’s disease. Ann Oncol 11:1405–1411

    CAS  PubMed  Google Scholar 

  135. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Briere J, Ferme C, Salles G (2007) Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin’s lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 25:1732–1740

    CAS  PubMed  Google Scholar 

  136. Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, Benedetti F, Pizzolo G (2002) Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin’s lymphoma. Ann Oncol 13:1908–1914

    CAS  PubMed  Google Scholar 

  137. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD (2012) Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120:3280–3287

    CAS  PubMed Central  PubMed  Google Scholar 

  138. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 91:475–481

    PubMed  Google Scholar 

  139. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160–1168

    CAS  PubMed  Google Scholar 

  140. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, Stefoni V, Castellucci P, Fina M, Farshad M, Pileri S, Baccarani M (2006) Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol 17:1296–1300

    CAS  PubMed  Google Scholar 

  141. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752

    CAS  PubMed  Google Scholar 

  142. Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben Bassat I, Polliack A (2009) Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann Oncol 21:126–132

    PubMed  Google Scholar 

  143. Wagstaff J, Steward W, Jones M, Deakin D, Todd I, Wilkinson P, Scarffe JH, Harris M, Crowther D (1986) Factors affecting remission and survival in patients with advanced Hodgkin’s disease treated with MVPP. Hematol Oncol 4:135–147

    CAS  PubMed  Google Scholar 

  144. Gobbi PG, Gobbi PG, Mazza P, Zinzani PL (1989) Multivariate analysis of Hodgkin’s disease prognosis. Fitness and use of a directly predictive equation. Haematologica 74:29–38

    CAS  PubMed  Google Scholar 

  145. Low SE, Horsman JM, Hancock H, Walters SJ, Hancock BW (2001) Prognostic markers in malignant lymphoma: an analysis of 1,198 patients treated at a single centre. Int J Oncol 19:1203–1209

    CAS  PubMed  Google Scholar 

  146. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dorken B, Muller-Hermelink HK, Duhmke E, Loeffler M (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395

    CAS  PubMed  Google Scholar 

  147. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614

    CAS  PubMed  Google Scholar 

  148. Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, Merli F, Iannitto E, Tura S, Ascari E (2001) Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer 91:1467–1478

    CAS  PubMed  Google Scholar 

  149. Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW (2005) Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom lymphoma group LY09 trial (ISRCTN97144519). J Clin Oncol 23:9208–9218

    CAS  PubMed  Google Scholar 

  150. Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA, Wilkinson PM, Gupta RK, James RD, Shamash J, Chang J, Crowther D, Lister TA (2002) ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 20:2988–2994

    CAS  PubMed  Google Scholar 

  151. Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, Gascoyne RD, Connors JM, Sehn LH (2012) International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 30:3383–3388

    PubMed  Google Scholar 

  152. Bierman PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, Armitage JO (2002) The International Prognostic Factors Project score for advanced Hodgkin’s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 13:1370–1377

    CAS  PubMed  Google Scholar 

  153. Gisselbrecht C, Mounier N, Andre M, Casanovas O, Reman O, Sebban C, Divine M, Brice P, Briere J, Hennequin C, Ferme C (2005) How to define intermediate stage in Hodgkin’s lymphoma? Eur J Haematol 75 (Suppl. 66):111–114

    Google Scholar 

  154. Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, Shulman LN, Coleman CN, Canellos G, Weinstein H (1993) Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 71:2613–2620

    CAS  PubMed  Google Scholar 

  155. Mauch PM (1994) Controversies in the management of early stage Hodgkin’s disease. Blood 83:318–329

    CAS  PubMed  Google Scholar 

  156. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15:528–534

    CAS  PubMed  Google Scholar 

  157. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Ferme C (1996) Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer 78:1293–1299

    CAS  PubMed  Google Scholar 

  158. Ferme C, Bastion Y, Lepage E, Berger F, Brice P, Morel P, Gabarre J, Nedellec G, Reman O, Cheron N (1995) The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol 6:543–549

    CAS  PubMed  Google Scholar 

  159. Lohri A, Barnett M, Fairey RN, O’Reilly SE, Phillips GL, Reece D, Voss N, Connors JM (1991) Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77:2292–2298

    CAS  PubMed  Google Scholar 

  160. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218

    CAS  PubMed  Google Scholar 

  161. Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G (1990) Salvage chemotherapy in Hodgkin’s disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1:123–127

    CAS  PubMed  Google Scholar 

  162. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A (2001) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 20:221–230

    Google Scholar 

  163. Josting A, Schmitz N (2004) Insights into 25 years of clinical trials of the GHSG: relapsed and refractory Hodgkin’s disease. In: Diehl V, Josting A (eds) 25 years German Hodgkin Study Group. Urban & Vogel, Munich, pp 89–99

    Google Scholar 

  164. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F (1987) MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol 5:556–561

    CAS  PubMed  Google Scholar 

  165. Perren TJ, Selby PJ, Milan S, Meldrum M, McElwain TJ (1990) Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin’s disease. Br J Cancer 61:919–923

    CAS  PubMed Central  PubMed  Google Scholar 

  166. Straus DJ, Myers J, Koziner B, Lee BJ, Clarkson BD (1983) Combination chemotherapy for the treatment of Hodgkin’s disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV). Cancer Chemother Pharmacol 11:80–85

    CAS  PubMed  Google Scholar 

  167. Salvagno L, Soraru M, Aversa SM, Bianco A, Chiarion SV, Pappagallo GL, Fiorentino MV (1993) Late relapses in Hodgkin’s disease: outcome of patients relapsing more than twelve months after primary chemotherapy. Ann Oncol 4:657–662

    CAS  PubMed  Google Scholar 

  168. Brada M, Eeles R, Ashley S, Nichols J, Horwich A (1992) Salvage radiotherapy in recurrent Hodgkin’s disease. Ann Oncol 3:131–135

    CAS  PubMed  Google Scholar 

  169. Josting A, Nogova L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Muller RP, Diehl V, Engert A (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23:1522–1529

    PubMed  Google Scholar 

  170. Leigh BR, Fox KA, Mack CF, Baier M, Miller TP, Cassady JR (1993) Radiation therapy salvage of Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 27:855–862

    CAS  PubMed  Google Scholar 

  171. Mauch P, Tarbell N, Skarin A, Rosenthal D, Weinstein H (1987) Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 5:544–549

    CAS  PubMed  Google Scholar 

  172. O’Brien PC, Parnis FX (1995) Salvage radiotherapy following chemotherapy failure in Hodgkin’s disease–what is its role? Acta Oncol 34:99–104

    PubMed  Google Scholar 

  173. Roach M III, Kapp DS, Rosenberg SA, Hoppe RT (1987) Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol 5:550–555

    PubMed  Google Scholar 

  174. Wirth A, Corry J, Laidlaw C, Matthews J, Liew KH (1997) Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 39:599–607

    CAS  PubMed  Google Scholar 

  175. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054

    CAS  PubMed  Google Scholar 

  176. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359:2065–2071

    CAS  PubMed  Google Scholar 

  177. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 11:2342–2350

    CAS  PubMed  Google Scholar 

  178. Argiris A, Seropian S, Cooper DL (2000) High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin’s disease. Ann Oncol 11:665–672

    CAS  PubMed  Google Scholar 

  179. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO (1996) High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin’s disease patients following first relapse after chemotherapy. Ann Oncol 7:151–156

    CAS  PubMed  Google Scholar 

  180. Czyz A, Lojko-Dankowska A, Dytfeld D, Nowicki A, Gil L, Matuszak M, Kozlowska-Skrzypczak M, Kazmierczak M, Bembnista E, Komarnicki M (2013) Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. Med Oncol 30:611

    PubMed Central  PubMed  Google Scholar 

  181. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol 20:467–475

    CAS  PubMed  Google Scholar 

  182. Fernandez de Larrea C, Martinez C, Gaya A, Lopez-Guillermo A, Rovira M, Fernandez-Aviles F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E (2010) Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol 21:1211–1216

    CAS  PubMed  Google Scholar 

  183. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy PL (2005) A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant 35:557–566

    CAS  PubMed  Google Scholar 

  184. Josting A (2005) Autologous transplantation in relapsed and refractory Hodgkin’s disease. Eur J Haematol Suppl 106:141–145

    Google Scholar 

  185. Lazarus HM, Loberiza FR Jr, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM (2001) Autotransplants for Hodgkin’s disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27:387–396

    CAS  PubMed  Google Scholar 

  186. Poen JC, Hoppe RT, Horning SJ (1996) High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 36:3–12

    CAS  PubMed  Google Scholar 

  187. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, Lopez A, Lahuerta JJ, Carreras E, Garcia-Conde J, Garcia-Larana J, Cabrera R, Jarque I, Carrera D, Garcia-Ruiz JC, Pascual MJ, Rifon J, Moraleda JM, Perez-Equiza K, Albo C, Diaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marin J, Mateos MV, Fernandez-Ranada JM, Sierra J, Conde E (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 16:625–633

    CAS  PubMed  Google Scholar 

  188. Viviani S, Di NM, Bonfante V, Di SA, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM (2010) Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma 51:1251–1259

    CAS  PubMed  Google Scholar 

  189. Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O’Brien JP, Portlock CS, Straus DJ, Phillips J, Fuks Z (1993) Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 11:1062–1070

    CAS  PubMed  Google Scholar 

  190. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L (2007) Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109:2481–2489

    PubMed  Google Scholar 

  191. Mocikova H, Pytlik R, Markova J, Steinerova K, Kral Z, Belada D, Trnkova M, Trneny M, Koza V, Mayer J, Zak P, Kozak T (2011) Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 52:1668–1674

    PubMed  Google Scholar 

  192. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, Moskowitz CH (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 116:4934–4937

    CAS  PubMed Central  PubMed  Google Scholar 

  193. Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, Kewalramani T, Moskowitz AJ, Rice RD, Maragulia J, Vanak J, Trippett T, Hamlin P, Horowitz S, Noy A, O’Connor OA, Portlock C, Straus D, Nimer SD (2010) High-dose chemo-radiotherapy for relapsed or refractory hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 148:890–897

    PubMed Central  PubMed  Google Scholar 

  194. Sucak GT, Ozkurt ZN, Suyani E, Yasar DG, Akdemir OU, Aki Z, Yegin ZA, Yagci M, Kapucu OL (2011) Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol 90:1329–1336

    PubMed  Google Scholar 

  195. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE (2004) Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma. Bone Marrow Transplant 33:1015–1023

    CAS  PubMed  Google Scholar 

  196. Stewart DA, Guo D, Gluck S, Morris D, Chaudhry A, de Metz C, Klassen J, Brown CB, Russell JA (2000) Double high-dose therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 26:383–388

    CAS  PubMed  Google Scholar 

  197. Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16:116–123

    CAS  PubMed  Google Scholar 

  198. Lumley MA, Milligan DW, Knechtli CJ, Long SG, Billingham LJ, McDonald DF (1996) High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin’s disease. Bone Marrow Transplant 17:383–388

    CAS  PubMed  Google Scholar 

  199. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 4:767–773

    CAS  PubMed  Google Scholar 

  200. Brice P, Bouabdallah R, Moreau P, Divine M, Andre M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P (1997) Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 20:21–26

    CAS  PubMed  Google Scholar 

  201. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood 81:1137–1145

    CAS  PubMed  Google Scholar 

  202. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 89:801–813

    CAS  PubMed  Google Scholar 

  203. Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E III, Kadin M, Antin J (1997) High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 3:98–106

    CAS  PubMed  Google Scholar 

  204. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A, Meloni G (1993) Autologous bone marrow transplantation for pediatric Hodgkin’s disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 11:2243–2249

    CAS  PubMed  Google Scholar 

  205. Kaloyannidis P, Voutiadou G, Baltadakis I, Tsirigotis P, Spyridonidis A, Repousis P, Balta A, Tsimberis S, Karakasis D, Sakellari I, Dervenoulas I, Harhalakis N, Anagnostopoulos A (2012) Outcomes of Hodgkin’s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:451–457

    PubMed  Google Scholar 

  206. Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z, Vanak J, Zelenetz AD, Moskowitz CH (2009) Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 146:158–163

    PubMed Central  PubMed  Google Scholar 

  207. Hasenclever D (2002) The disappearance of prognostic factors in Hodgkin’s disease. Ann Oncol 13(Suppl 1):75–78

    PubMed  Google Scholar 

  208. Cosset JM, Mauch PM (1998) The role of radiotherapy for early stage Hodgkin’s disease: limitations and perspectives. Ann Oncol 9(Suppl 5):S57–S62

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section 3994, Department of Oncology and Haematology, The Finsen Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark

    Lena Specht MD, PhD

  2. Institut für Medizinische Informatik, Statistik und Epidemiologie (IMISE), Univeristät Leipzig, Härtelstr. 16-18, Leipzig, 04107, Germany

    Dirk Hasenclever

Authors
  1. Lena Specht MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Hasenclever
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lena Specht MD, PhD .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Köln Klinik I für Innere Medizin, Köln, Germany

    Andreas Engert

  2. Memorial Sloan - Kettering Cancer Center, New York, New York, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing

About this chapter

Cite this chapter

Specht, L., Hasenclever, D. (2015). Prognostic Factors. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12505-3_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12504-6

  • Online ISBN: 978-3-319-12505-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation